HCL and UNLEASH Partner to Develop Solutions for Aquatic Ecosystem Conservation
20.5.2022 18:59:00 EEST | Business Wire | Press release
HCL Group and UNLEASH, a global innovation program for the UN Sustainable Development Goals (SDGs), announced a year-long collaboration to mobilize youth and develop innovative solutions to promote aquatic ecosystem conservation. These solutions will aim to tackle challenges from Source (mountains & glaciers) to Sink (oceans and seas) and their links to terrestrial ecosystems.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220520005178/en/
Nature and ocean conservation play a critical role in our survival. Terrestrial and aquatic ecosystems provide us with food, water, oxygen, energy, and medicines. They regulate our climate, provide pollination to crops, and reduce the impact of natural hazards.
Despite the vital importance of our planet’s ecosystems, we are experiencing a human-caused deterioration of our natural habitats: human activity has altered almost 75% of the Earth’s terrestrial surface, squeezing wildlife and nature into an ever-smaller corner.1 Furthermore, ocean heat is at record levels and every year up to 12 million metric tonnes of plastic enter the ocean, damaging ecosystems around the world. Without maintaining healthy and biodiverse terrestrial and aquatic ecosystems, the progress on the remaining United Nations’ SDGs is at critical risk.
To tackle such challenges, UNLEASH and HCL will collaborate to establish a year of youth-led action. Specifically, the partnership will allow youth to develop solutions encompassing SDG 14 (Life below water) and SDG 15 (Life on land), and explore synergies with other SDGs as well. During the process, they will be guided by industry experts and receive hands-on support to ensure that solutions are relatable to the context and feasible in practice.
HCL Group with its large presence in business through HCL Technologies, HCL Infosystems and HCL Healthcare; and its social development organizations including the philanthropic Shiv Nadar Foundation and The Habitats Trust, and its CSR arm – HCL Foundation, has been tackling real on-ground issues related to the SDGs. The Group with its breadth of experience across different sectors and its holistic and powerful sustainability charter is the perfect partner for UNLEASH to successfully push its SDGs innovation efforts.
“Innovation, entrepreneurship, humanity and a people-centric culture are part of HCL’s core, and it is important to us that our progress is reflected in the development of a better world. Our various entities have already been driving important projects to help create a positive impact for the people and the planet. HCL’s collaboration with UNLEASH in bringing innovation to the SDGs, and specifically to the preservation of nature and ocean conservation is an essential step in our overall sustainability efforts”, said Roshni Nadar Malhotra, CEO of HCL, Chairperson of HCL Technologies, Trustee of Shiv Nadar Foundation & Founder of The Habitats Trust.
With HCL’s continuous support on the thematic track From Source to Sink, UNLEASH Talents will have the opportunity to work on localized challenges through joining an UNLEASH Hack at the Shiv Nadar University, Delhi NCR (part of the HCL Group). Earlier this year, UNLEASH Talents participated in three other UNLEASH Hacks related to this theme, exploring challenges of water ecosystems from the Mediterranean, the Danube, Haiti and Hawaii and defining solutions that can drive positive local impact on those regions. The partnership will help scale an existing early-stage solution in the biodiversity space through enrolment in an incubation program, UNLEASH Plus. Thematic insight sessions will be organized throughout 2022, providing inspiration and key learnings on the essence of the theme. These year-long efforts will culminate in the Global Innovation Lab in India that will witness a gathering of 1000+ talented youth for a week long innovation process and help them develop solutions for Indian and global challenges within aquatic and terrestrial ecosystem conservation. The best solutions from the Lab will take home grant prizes to kick-start implementation of the developed solutions. Through the course of this partnership, HCL will enable access to its celebrated business leaders, technical experts, and faculty and academicians of global repute to serve as facilitators, mentors and experts that will help participants across the various programs to develop innovative solutions.
The partnership enables UNLEASH to dive deep into SDG14 and SDG15, and truly establish a community of changemakers, working with nature challenges.
“HCL’s journey in innovation and development is an inspiration for the entire UNLEASH Community. We are very grateful for their partnership on an important matter such as the aquatic conservation of our planet and finding solutions for its preservation through our different programs during the course of this year”, said UNLEASH Chairman Flemming Besenbacher.
About HCL Group
Founded in 1976 as one of India’s original IT garage start-ups, HCL is a pioneer of modern computing with many firsts to its credit, including the introduction of the 8-bit microprocessor-based computer in 1978 well before its global peers. Today, the HCL Group has business presence across sectors including technology and healthcare and comprises three group companies –HCL Technologies, HCL Infosystems and HCL Healthcare. The Group generates annual revenues of over US$11.5 billion with more than 209,000 employees operating across 52 countries.
The Group also includes one of India’s most prolific philanthropic foundations – the Shiv Nadar Foundation. Established in 1994, the Foundation is committed to the creation of a more equitable, merit-based society by empowering individuals through transformational education. Over the last 27 years, it has invested over US$1billion in seven landmark institutions and initiatives across education and art. The Habitats Trust, also a philanthropic Foundation within the HCL Group, specifically works towards protecting natural habitats and their indigenous species of flora and fauna. Established in 2018, the young foundation is undertaking important initiatives that will help secure a positive future for wild species and their habitats.
HCL Foundation, the Corporate Social Responsibility arm of HCL, has instituted flagship programs and initiatives to contribute towards SDGs. Its work is helping bring about lasting positive impact on the people and planet, through long-term sustainable programs, and ensure equitable access, opportunities, and holistic development for all.
For further information, visit www.hcl.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220520005178/en/
Contact information
For any queries or information, please contact:
Sadaf Khan | Sadaf-k@hcl.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
